Abbonarsi

Colon capsule endoscopy compared with other modalities in the evaluation of pediatric Crohn’s disease of the small bowel and colon - 31/05/16

Doi : 10.1016/j.gie.2015.08.070 
Salvatore Oliva, MD 1, , Salvatore Cucchiara, MD, PhD 1, Fortunata Civitelli, MD 1, Emanuele Casciani, MD 2, Giovanni Di Nardo, MD 1, Cesare Hassan, MD, PhD 3, Paola Papoff, MD, PhD 4, Stanley A. Cohen, MD 5
1 Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy 
2 Radiology DEA, Sapienza-University of Rome, Rome, Italy 
3 Gastrointestinal Endoscopy Unit, Chatolic University of Rome, Rome, Italy 
4 Pediatric Intensive Care Unit, Sapienza-University of Rome, Rome, Italy 
5 Children's Center for Digestive Health Care, Atlanta, Georgia, USA 

Reprint requests: Salvatore Oliva, MD, Department of Pediatrics and Childhood Neuropsychiatry, Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Viale Regina Elena 324–00161 Roma, Italy.Department of Pediatrics and Childhood Neuropsychiatry, Pediatric Gastroenterology and Liver Unit, Sapienza University of RomeViale Regina Elena 324–00161 RomaItaly

Abstract

Background and Aims

Data on colon capsule endoscopy (CCE) in evaluating the small bowel and colon concurrently are rare. This study aimed to evaluate the accuracy of CCE in assessing disease activity of the small bowel and colon in pediatric Crohn’s disease (CD) by comparison with magnetic resonance enterography (MRE), small-intestine contrast US (SICUS), and ileocolonoscopy.

Methods

We prospectively enrolled 40 consecutive patients (22 male, 18 female, mean age 13.1 ± 3.1 years) with CD of the small bowel and colon. All underwent SICUS, MRE, CCE, and ileocolonoscopy sequentially over 5 days. All investigators were blinded to patient history and test results. Patients were classified as active or inactive for the small bowel and the colon according to specific criteria for each tool (simple endoscopic score for CD, Lewis score, US and magnetic resonance parameters of activity). For colon mucosa evaluation, ileocolonoscopy was the comparator. For the small bowel, a consensus panel was convened.

Results

Sensitivity of CCE to detect colon inflammation was 89%, and specificity was 100%. The positive predictive value (PPV) and negative predictive value (NPV) of CCE for colon inflammation were 100% and 91%, respectively. In the small bowel, CCE showed 90% sensitivity, 94% specificity, with PPV and NPV of 95% and 90%, respectively. Accuracy parameters for SICUS (sensitivity 90%, specificity 83%) and MRE (sensitivity 85%, specificity 89%) were lower than those for CCE. No serious adverse events related to the CCE procedure or preparation were reported.

Conclusions

CCE is of great usefulness in evaluating both small bowel and colon mucosa in pediatric CD. This single, noninvasive tool makes it possible to evaluate the small-bowel and the colon concurrently with high diagnostic accuracy. Future multicenter studies need to define the role of CCE in the routine management of pediatric patients with CD. (Clinical trial registration number: NCT02199626.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : AFR, CCE, CD, IBD, MRE, NPV, PEG, PPV, SICUS


Mappa


 DISCLOSURE: C. Hassan and S. Cohen are consultants for Given Imaging. All other authors disclosed no financial relationships relevant to this article.
 If you would like to chat with an author of this article, you may contact Dr Oliva at salvatore.oliva@uniroma1.it.


© 2016  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 83 - N° 5

P. 975-983 - maggio 2016 Ritorno al numero
Articolo precedente Articolo precedente
  • Challenges in detection and real-time diagnosis of dysplasia in Crohn’s colitis: the search still continues
  • Anna M. Buchner
| Articolo seguente Articolo seguente
  • A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy
  • Daniel J. Pambianco, Keith M. Borkett, Dennis S. Riff, Peter J. Winkle, Howard I. Schwartz, Timothy I. Melson, Karin Wilhelm-Ogunbiyi

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.